Moderna (MRNA) Stock Climbs 16% on Melanoma Vaccine Breakthrough

TLDR Moderna shares surged 16% to $50 on Wednesday following positive five-year melanoma vaccine trial data Combined treatment with Merck’s Keytruda showed 49% reduction in cancer recurrence or death risk Company is diversifying beyond COVID vaccines into cancer treatments and respiratory vaccines Analysts maintain Hold rating with $29.93 average price target, implying 39.91% downside Additional [...]

The post Moderna (MRNA) Stock Climbs 16% on Melanoma Vaccine Breakthrough appeared first on Blockonomi.